AR068837A1 - Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion - Google Patents

Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion

Info

Publication number
AR068837A1
AR068837A1 ARP080104405A ARP080104405A AR068837A1 AR 068837 A1 AR068837 A1 AR 068837A1 AR P080104405 A ARP080104405 A AR P080104405A AR P080104405 A ARP080104405 A AR P080104405A AR 068837 A1 AR068837 A1 AR 068837A1
Authority
AR
Argentina
Prior art keywords
amino
trifluoro
salts
propanoic
preeparation
Prior art date
Application number
ARP080104405A
Other languages
English (en)
Inventor
Wenxue Wu
Shinya Limira
Hui-Yin Li
Qiuling Song
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR068837A1 publication Critical patent/AR068837A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/34Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen formas solidas de ácido (S)-2-amino-3-(4(2-amino-6-((R -2,2,2,trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico y sus sales, el compuesto cristalino en forma de propanoato-tosilato anhidro, hidrato, monohidrato, utiles para tratar el síndrome carcinoide y trastornos gastrointestinales e intestino irritable. Reivindicacion 4: El compuesto cristalino de acuerdo con la reivindicacion 3, caracterizado porque tiene un punto de fusion de aproximadamente 241 °C. Reivindicacion 5: El compuesto cristalino de acuerdo con la reivindicacion 3, caracterizado porque tiene un patron de difraccion de polvos por rayos X que comprende un pico en uno o varios de aproximadamente 3,5, 7,0, 8,6, 10,9, 13,5, 14,0, 15,1, 17,3, y/o 20,5 grados 2 thita. Reivindicacion 6: El compuesto de acuerdo con la reivindicacion 3, caracterizado porque tiene un patron de difraccion de polvos por rayos X sustancialmente igual al mostrado en la Figura 1.
ARP080104405A 2007-10-08 2008-10-08 Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion AR068837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97830307P 2007-10-08 2007-10-08

Publications (1)

Publication Number Publication Date
AR068837A1 true AR068837A1 (es) 2009-12-09

Family

ID=40344344

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104405A AR068837A1 (es) 2007-10-08 2008-10-08 Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion

Country Status (20)

Country Link
US (1) US20090099206A1 (es)
EP (1) EP2231618A1 (es)
JP (1) JP2010540665A (es)
KR (1) KR20100066548A (es)
CN (1) CN101932563A (es)
AR (1) AR068837A1 (es)
AU (1) AU2008310979A1 (es)
BR (1) BRPI0818350A2 (es)
CA (1) CA2701904A1 (es)
CL (1) CL2008002980A1 (es)
CO (1) CO6270323A2 (es)
EA (1) EA201070455A1 (es)
EC (1) ECSP10010162A (es)
IL (1) IL204582A0 (es)
MX (1) MX2010003803A (es)
PE (1) PE20091213A1 (es)
TW (1) TW200932729A (es)
UY (1) UY31381A1 (es)
WO (1) WO2009048864A1 (es)
ZA (1) ZA201001870B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
CA2635531C (en) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法
AU2009231892A1 (en) 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
EP2504008A1 (en) * 2009-11-23 2012-10-03 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
WO2013148978A1 (en) * 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
MX2021005559A (es) * 2018-11-14 2021-09-10 Altavant Sciences Gmbh Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización.
EP4163271A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd PROCESS FOR PREPARING METHYL-(S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDIN-4-YL)PHENYLPROPIONATE AND SALT THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7382793B1 (en) * 2002-01-17 2008-06-03 Juniper Networks, Inc. Systems and methods for determining the bandwidth used by a queue
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
CA2635531C (en) * 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CA2691003A1 (en) * 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
EA201070127A1 (ru) * 2007-07-11 2010-08-30 Лексикон Фармасьютикалз , Инк. Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления
US20090029993A1 (en) * 2007-07-26 2009-01-29 Qingyun Liu Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein

Also Published As

Publication number Publication date
US20090099206A1 (en) 2009-04-16
WO2009048864A1 (en) 2009-04-16
PE20091213A1 (es) 2009-08-26
EP2231618A1 (en) 2010-09-29
UY31381A1 (es) 2009-04-30
KR20100066548A (ko) 2010-06-17
CA2701904A1 (en) 2009-04-16
AU2008310979A1 (en) 2009-04-16
BRPI0818350A2 (pt) 2017-10-10
CN101932563A (zh) 2010-12-29
CO6270323A2 (es) 2011-04-20
JP2010540665A (ja) 2010-12-24
TW200932729A (en) 2009-08-01
ZA201001870B (en) 2011-06-29
IL204582A0 (en) 2010-11-30
EA201070455A1 (ru) 2010-08-30
CL2008002980A1 (es) 2009-03-20
MX2010003803A (es) 2010-04-21
ECSP10010162A (es) 2010-06-29

Similar Documents

Publication Publication Date Title
AR068837A1 (es) Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
PE20131343A1 (es) Derivados de acido benzoico
PE20061098A1 (es) COMPUESTOS IMIDAZO[1,2-a] PIRIDINILO COMO INHIBIDORES DE VEGF-R2
RS54653B1 (en) 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
PE20160874A1 (es) Compuestos quimicos
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
CL2008002315A1 (es) Compuestos derivados de acido piridin, pirimidin y quinolin aminonbenzoico; composicion y combinacion farmaceuticas; y uso para el tratamiento de una enfermedad susceptible de aliviarse mediante la inhibicion de deshidroorotato deshidrogenasa tales como artritis reumatoide, espondilitis anquilosante, esclerosis multiple, psoriasis, entre otras.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
CO5670355A2 (es) Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
BRPI0506610A (pt) montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
CY1118284T1 (el) Βεσυλικα και τοσυλικα αλατα ενος παραγωγου διυδροκιναζολινης και χρηση αυτων ως αντιικων παραγοντων
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
PE20091087A1 (es) COMPUESTOS DERIVADOS DE 6-FENIL-1H-IMIDAZO[4,5-c]PIRIDINA-4-CARBONITRILO COMO INHIBIDORES DE CATEPSINA S Y/O CATEPSINA K
MX2020013311A (es) Composicion farmaceutica para administracion topica.
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
CL2021002365A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
CO2020006206A2 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
PH12019501566A1 (en) Amide compounds and use thereof
BR112017018230A2 (pt) forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina
ES2915123R1 (es) Proceso para la síntesis de la sal sódica del ácido 4-[[(1R)-2-[5-(2-fluoro-3-metoxifenil)-3-[[2-fluoro-6-(trifluorometil)-fenil]metil]-3,6-dihidro-4-metil-2,6-dioxo-1(2H)-pirimidinil]-1-feniletil]amino]-butanoico (sal sódica de Elagolix) y productos intermedios de dicho proceso
AR065602A1 (es) Polimorfos de s , s dioxido del acido 7 - ( (3 - cloro-6 , 11 - dihidro-6-metildibenzo ( c , f ) (1 , 2 ) tiazepin- 11- il) amino ) heptanoico y metodos para su preparacion y uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure